CLINICAL STUDIES/TRIALS

临床研究/试验

• 批准号: 6424525
• 负责人: ALAN N. HOUGHTON
• 金额: $ 23.06万
• 依托单位: SLOAN-KETTERING INST CAN RESEARCH
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-01 至 2002-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6424525
• 关键词: antineoplastics; chimeric proteins; cis platinum compound; clinical research; clinical trial phase I; combination cancer therapy; combination chemotherapy; doxorubicin; drug screening /evaluation; human subject; human therapy evaluation; isolation perfusion; laboratory rat; lung neoplasms; metastasis; neoplasm /cancer chemotherapy; neoplasm /cancer immunology; neoplasm /cancer immunotherapy; neoplasm /cancer pharmacology; neoplasm /cancer surgery; neoplasm /cancer vaccine; nonhuman therapy evaluation; sarcoma; vaccine development

This Clinical Studies/Trials Project is based on accomplishment over the past several years and continues to support two major initiatives (1) intensification of chemotherapy by regional Infusion" of the lung for patients with Soft Tissue Sarcoma metastatic to the lung. (2) Preclinical and clinical immunologic studies of high risk STS patients. In section 1a, phase I and phase II trials are ongoing and planned. Tissue obtained from patients in these studies will be sent to investigators in project 1b, 2, and 3 for analysis of tumor antigens, cell cycle regulators and mechanisms of drug resistance. In section 1b, preclinical studies are planned to define novel approaches for the development of tumor vaccines in order to delay or prevent progression of disease. Little is known about potential target on STS, except gangliosides and SYT_SSX fusion proteins, both under study in this Program Project. Therefore, we plan to identify antigens expressed by screening DNA libraries derived from autologous tumors, investigate peptide and DNA immunization against SYT_SSX fusion proteins, and evaluate immunizations against combinations of gangliosides in high risk patients. ?

该临床研究/试验项目基于以下成就： 过去几年并继续支持两项重大举措 (1) 通过肺部局部输注强化化疗 软组织肉瘤转移至肺部的患者。 (2) 临床前 以及高危 STS 患者的临床免疫学研究。在第 1a 节中， 第一阶段和第二阶段试验正在进行中并计划进行。组织获得自 这些研究中的患者将被送往项目 1b、2 和 3 用于分析肿瘤抗原、细胞周期调节因子及其机制 耐药性。在第 1b 节中，计划进行临床前研究来定义 开发肿瘤疫苗的新方法以延缓 或预防疾病的进展。对潜在目标知之甚少 在 STS 上，除了神经节苷脂和 SYT_SSX 融合蛋白，两者都在 在此计划项目中学习。因此，我们计划鉴定抗原 通过筛选源自自体肿瘤的 DNA 文库来表达， 研究针对 SYT_SSX 融合的肽和 DNA 免疫 蛋白质，并评估针对组合的免疫接种 高危患者使用神经节苷脂。 ？